Immunological hallmarks of stromal cells in the tumour microenvironment

By S. Turley, V. Cremasco, Jillian L Astarita. Nature reviews. Immunology, 2015

1,031 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/9ac693eefa37ce6b448f10f6cea7d72bdde7ca88

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Miriam Merad
2. Atul J. Butte
3. Judy H. Cho
4. Zicheng Hu
5. D. Aran

In Oncology

1. Zicheng Hu
2. Atul J. Butte
3. D. Aran
4. Sigrid A. Langhans

Citations in the corpus

• Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning (2018, background): “The response to therapeutic compounds may range from drug resistance to enhanced sensitivity based on tissue-specific composition of the ECM, the interaction with stromal cells and the presence of immunomodulatory molecules (Turley et al., 2015; Johansson et al., 2016; Stock et al., 2016).”
• Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures (2019, background): “For example, differences in the compositions of resident cell types within the TME, including cytotoxic T cells, helper T cells, dendritic cells (DCs), tumor-associated macrophages, mesenchymal stem cells, and associated inflammatory pathways, have been reported in patients with cancer (5, 6, 9, 10)”
• PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “Similarly, maturation of MDSC to TAM and secretion of pro-inflammatory cytokines (IFN-γ) from TAM suppress T-cell functions, thus providing positive modulation of PD-1 and PD-L1 interaction (Turley et al., 2015).”
• xCell: digitally portraying the tissue cellular heterogeneity landscape (2017, methodology): “Second, current methods focus on only a very narrow range of the tumor microenvironment, usually a subset of immune cell types, and thus do not account for the further richness of cell types in the microenvironment, including blood vessels and other different forms of cell subsets [14, 15].”